Virpax Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, initially filed on April 18, 2024. The company seeks to have the registration become effective on May 6, 2024, at 5:00 p.m. Eastern Time or as soon as possible thereafter. This request was communicated through a letter addressed to Daniel Crawford at the SEC, with the understanding that the company acknowledges its responsibilities under federal securities laws regarding the issuance of securities covered by the statement. Virpax Pharmaceuticals has authorized Leslie Marlow and Melissa Palat Murawsky from Blank Rome LLP to modify or withdraw the acceleration request if necessary. The company's CEO, Gerald Bruce, signed the letter, indicating the formal nature of the request.

Virpax Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, initially filed on April 18, 2024. The company seeks to have the registration become effective on May 6, 2024, at 5:00 p.m. Eastern Time or as soon as possible thereafter. This request was communicated through a letter addressed to Daniel Crawford at the SEC, with the understanding that the company acknowledges its responsibilities under federal securities laws regarding the issuance of securities covered by the statement. Virpax Pharmaceuticals has authorized Leslie Marlow and Melissa Palat Murawsky from Blank Rome LLP to modify or withdraw the acceleration request if necessary. The company's CEO, Gerald Bruce, signed the letter, indicating the formal nature of the request.